Hyperhomocysteinemia Clinical Trial
Official title:
Effectiveness of a Micronutrient Supplement to Lower Plasma Homocysteine in Non-pregnant Women of Reproductive Age
This micronutrient supplementation study is a 3-arm randomized controlled trial, unblinded,
with 125 women per arm. Non-pregnant, non-lactating healthy women of reproductive age in West
Kiang, The Gambia, will be randomized to 12 weeks of daily supplementation of either a) novel
micronutrient supplement, b) a United Nations International Multiple Micronutrient
Preparation (UNIMMAP) tablet or c) no intervention (control). The novel micronutrient
supplement is a drink powder providing 800 µg folic acid, 5.2 µg cyanocobalamin (B12), 2.8 mg
Riboflavin-5'-phosphate (B2), and 4g trimethylglycine (betaine). UNIMMAP contains 15
micronutrients at the Recommended Daily Allowance level. The aim is to test the effectiveness
of the supplements on correcting micronutrient deficiencies in the dry season and to reduce
homocysteine levels. The hypothesis is that the new drink powder will be the most effective
supplement, causing a reduction in 1 µmol/L compared to the control group after
supplementation.
The supplements will be supplied to participants on a daily basis by Community-based Birth
Attendants (CBCs). The CBCs will observe consumption of the supplement. The novel
micronutrient supplement will be provided in powder form with instructions to dissolve one
sachet in a cup of 200ml water. UNIMMAP will be provided in capsule form to be taken with
water. Women will provide one 10ml fasted venous blood sample at baseline and another after 6
and 12 weeks of supplementation. At each time point they will also have their blood pressure
and anthropometry assessed and provide a urine pregnancy test.
Correcting micronutrient deficiencies is extremely important for the long-term health of
women, and in particular around the time of conception and throughout pregnancy since
micronutrients are needed for the proper physical and cognitive development of the baby.
Certain micronutrients are required for adding a methyl group to places on DNA ('DNA
methylation'). The pattern of these methyl groups can help determine whether a gene is
switched on or off. Correct functioning of DNA methylation processes is therefore of critical
importance for fetal development. High levels of homocysteine can impede DNA methylation,
therefore supplements that reduce homocysteine may not only be beneficial for the mother but
also for the developing child. The most effective supplement in this trial will be considered
for testing in larger pregnancy trials.
In rural Gambia women experience considerable variation in their diet by season. In the dry
season women have particular micronutrient deficiencies that can disrupt one-carbon
metabolism pathways. In the dry season women have lower levels of most of the B vitamins and
higher levels of homocysteine compared to the rainy season. The goal of this trial is to test
two nutritional interventions to see which one works best in providing micronutrients in the
ratio and quantity necessary for optimal 1-carbon metabolism in the dry season. The primary
end point is to assess which supplement is most effective in reducing plasma homocysteine.
This is a 3-arm randomized controlled trial, unblinded, with 125 women per arm. Non-pregnant,
non-lactating healthy women of reproductive age in West Kiang will be randomized to 12 weeks
of daily supplementation of either a) novel micronutrient drink powder supplement, b)
existing available micronutrient supplement (UNIMMAP) or c) no intervention (control). The
novel drink powder provides 800 µg folic acid, 5.2 µg cyanocobalamin (B12), 2.8 mg
Riboflavin-5'-phosphate (B2), and 4g trimethylglycine (betaine). This dose is twice the
Recommended Daily Allowance for folic acid, B12 and B2. The UNIMMAP tablet provides 15
micronutrients (vitamins A, D, E, B1, B2, B6, B12, C, Niacin, Folic Acid, Iron, Zinc, Copper,
Iron, Selenium) at the Recommended Daily Allowance level.
Potentially eligible participants will be identified through the Keneba Health and
Demographic Surveillance System in all 35 villages of West Kiang region of The Gambia. Field
assistants will visit the homes of potentially eligible participants to provide full
information about the purpose and methods of the study, potential risks and benefits, and
participants' rights. Full inclusion and exclusion criteria will be assessed. Participants
will then be asked to provide a signed or thumb-printed informed consent before being
enrolled into the study.
The supplements will be supplied to participants on a daily basis by Community-based Birth
Companions (CBCs). The novel drink powder will be provided in daily sachets and dissolved in
200ml water. UNIMMAP will be provided in capsule form to be taken with water. The CBCs will
observe consumption of the supplement. Participants will be given 7 coloured cards at the
start of each week. Every day they will give the CBC one card and receive their supplement.
Each week a field assistant will collect data on compliance by recording card collection in
liaison with the CBC.
Women will provide one 10mL fasted venous blood sample at baseline and another after 6 and 12
weeks of supplementation. At each time point they will also have their blood pressure and
anthropometry (weight and height) assessed and provide a urine pregnancy test. Women will be
brought to the Medical Research Council Gambia (MRCG) field station at Keneba for the
baseline, 6 week (mid-line) and 12 week (end-line) data collection visits. Participants will
be followed-up after the intervention period for a further 3 weeks to monitor any adverse
effects.
The fasted 10mL baseline, 6 week and 12 week blood samples will be taken by venepuncture into
EDTA monovettes and kept on ice. Within one hour of collection the samples will be processed
by the laboratory in Keneba to centrifuge the samples, separate the plasma and store plasma
and red blood cell aliquots at -70°C. One plasma aliquot will be analysed in Keneba to
measure homocysteine using the Cobas Integra 400 Plus analyser.
The hypothesis is that the novel micronutrient supplement will reduce plasma by at least 1
µmol/L compared to the control group after 12 weeks of daily supplementation. It will be more
effective in reducing plasma homocysteine than existing UNIMMAP tablets.
This trial is powered to study to detect a decrease of 1 µmol/L homocysteine with 80% power
and 95% confidence. The trial statistician will use a linear regression model to determine
the mean difference between intervention and control homocysteine at 12 weeks adjusted for
baseline homocysteine, week 12 age and week 12 body mass index.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00005482 -
Homocyst(e)Ine, Vitamin Status, and CVD Risk
|
N/A | |
Recruiting |
NCT06264570 -
Evaluation of a Genetically Determined Personalized Approach in Prescribing Biologically Active Substances in Patients With Elevated Blood Homocysteine Levels.
|
N/A | |
Completed |
NCT02392767 -
Effect of L-Arginine and Pycnogenol on Light to Moderate Hypertension and Endothelial Function
|
N/A | |
Completed |
NCT02540642 -
Effect of Vitamin B12 Supplementation on Glycaemic Control in Uncontrolled Hyperhomocysteinemic Type 2 Diabetic Patients
|
N/A | |
Completed |
NCT01371357 -
The Effects of 8-week Choline, Betaine, and Folic Acid Supplementation on Plasma Homocysteine Concentration During Guanidinoacetic Acid Loading in Young Healthy Volunteers
|
Phase 3 | |
Withdrawn |
NCT01871740 -
CSPPT- Chronic Kidney Diseases Study
|
Phase 4 | |
Not yet recruiting |
NCT03720249 -
Effects of Supplementation of Compound Nutrients on Plasma Homocysteine in Chinese Adults With Hyperhomocysteinemia
|
N/A | |
Completed |
NCT06163443 -
Evaluating the Impact of B Vitamin Supplementation (Soloways™) on Homocysteine and LDL-C Levels in Patients With MTHFR, MTR, and MTRR Polymorphisms.
|
N/A | |
Completed |
NCT01391416 -
Prevalence Of Hyperhomocysteinemia In Thai Chronic Kidney Disease (CKD) Patients
|
N/A | |
Completed |
NCT00004495 -
Randomized Study of Folic Acid Therapy for Hyperhomocysteinemia in Patients With End Stage Renal Disease Receiving Hemodialysis
|
N/A | |
Completed |
NCT00755664 -
Effects of Low-dose Complex B-vitamins on Homocysteine and Framingham Risk Score Among Chinese Elderly
|
Phase 3 | |
Completed |
NCT02961972 -
Effects of Oral Supplementation With Creatine on Systemic Microvascular Endothelial Function in Vegetarian Individuals
|
N/A | |
Completed |
NCT02860338 -
COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE
|
N/A | |
Completed |
NCT00737126 -
The Effect of Folic Acid Administration in the Progression of Microalbuminuria
|
N/A | |
Completed |
NCT00626223 -
5-methyltetrahydrofolate Survival and Inflammation in ESRD Patients
|
N/A | |
Completed |
NCT03631238 -
The Dual Impact of Homocysteine and Cholesterol on Cognitive Functions
|
||
Completed |
NCT03376490 -
Study of the Association of Muscle Strength, Balance and Other Factors With Vitamin Levels Among Elderly Diabetics
|
N/A | |
Enrolling by invitation |
NCT02817503 -
Feasibility Study of the Intensive Systolic Blood Pressure Control
|
Phase 4 | |
Completed |
NCT01766310 -
Effect of Folic Acid Supplementation on Plasma Homocysteine Level in Obese Children
|
Phase 4 | |
Completed |
NCT00005483 -
Plasma Homocysteine Distribution in the United States
|
N/A |